{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:54:17Z","timestamp":1791262457631,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clozapine is the gold standard for treatment-resistant schizophrenia (TRS). It requires strict monitoring of full blood count (FBC), due to the risk of neutropenia and agranulocytosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case history<\/jats:title>\n                    <jats:p>\n                      AB is a woman in her mid-40s with TRS, diagnosed with invasive ductal carcinoma of the right breast. She was commenced on a chemotherapy regimen of docetaxel, carboplatin, trastuzumab, and pertuzumab. Four days after the initial infusion, AB developed neutropenia with an absolute neutrophil count of 0.2 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L. In accordance with local protocols and discussion with the Clozapine Patient Monitoring Service (CPMS), clozapine was immediately discontinued. Two weeks after clozapine cessation, AB displayed catatonic symptoms characterised by mutism, posturing, and automatic obedience, scoring 27 on the Bush\u2013Francis Catatonia Rating Scale (BFCRS). A positive lorazepam challenge confirmed the diagnosis of clozapine-withdrawal catatonia. Despite regular high-dose benzodiazepines and treatment with antipsychotics, AB\u2019s presentation continued to deteriorate, characterised by prominent delusions and hallucinations, impeding oncological treatment. AB was seen extensively by liaison psychiatry and treated with high-dose typical and atypical antipsychotics; however, she failed to respond adequately to treatment. Given AB\u2019s extensive previous history of management on clozapine without previous haematological disturbance and ongoing decline in mental state, coupled with the timeline of symptoms 4 days after the administration of chemotherapy agents associated with neutropenia, namely, carboplatin, the decision was taken to reinstate clozapine. Following titration of clozapine and transfer to a specialist psychiatric unit, AB\u2019s symptoms resolved rapidly, allowing for the successful completion of chemotherapy. Carboplatin was omitted in subsequent cycles, with no further episodes of neutropenia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case highlights the diagnostic challenge of neutropenia in psychiatric patients on clozapine, who are also undergoing treatment for comorbid medical conditions. The presence of neutropenia in clozapine patients may lead to diagnostic overshadowing and delay the diagnosis of the underlying cause of neutropenia, resulting in delays to treatment as well as unnecessary cessation of clozapine and risk of relapse. Furthermore, this case highlights the risk of catatonia associated with the withdrawal of clozapine and the importance of its rapid identification and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinicians should consider differing aetiologies of neutropenia in clozapine patients, especially those undergoing chemotherapy. Furthermore, clinicians should be skilled in recognising catatonia and initiating prompt treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1863699","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:24Z","timestamp":1791260724000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complications of clozapine cessation in the context of chemotherapy-related neutropenia\u2014a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Colm","family":"Sweeney","sequence":"first","affiliation":[{"name":"Department of Psychological Medicine, St James Hospital","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Rush","sequence":"additional","affiliation":[{"name":"St Patrick\u2019s University Hospital","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O\u2019Dwyer","sequence":"additional","affiliation":[{"name":"St Patrick\u2019s University Hospital","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Mac Eochagain","sequence":"additional","affiliation":[{"name":"Department of Oncology, St James Hospital","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3is\u00edn","family":"Plunkett","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, St James Hospital","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","unstructured":"The mechanism of action of clozapine\n          \n          \n            \n              Morrison\n              PD\n            \n            \n              Jauhar\n              S\n            \n            \n              Young\n              AH\n            \n          \n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852925100576","article-title":"Clozapine and anti-cancer agents: a systematic literature review of case reports","volume":"30","author":"Honor","year":"2025","journal-title":"CNS Spectrums"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/genes14030689","article-title":"Treatment-resistant schizophrenia, clozapine resistance, genetic associations, and implications for precision psychiatry: A scoping review","volume":"14","author":"Ying","year":"2023","journal-title":"Genes (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck","year":"1999","journal-title":"Am J Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2023-0113","article-title":"The diagnosis and treatment of catatonia","volume":"23","author":"Rogers","year":"2023","journal-title":"Clin Med (Lond)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaclp.2025.05.001","article-title":"Catatonia: american psychiatric association resource document","volume":"66","author":"Wilson","year":"2025","journal-title":"J Acad Consultation-Liaison Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.17060123","article-title":"Catatonia under-diagnosis in the general hospital","volume":"30","author":"Llesuy","year":"2018","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.25cr04014","article-title":"Clozapine withdrawal-induced catatonia","volume":"27","author":"Wilkinson","year":"2025","journal-title":"Prim Care Companion CNS Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0192-9","article-title":"Review of withdrawal catatonia: what does this reveal about clozapine","volume":"8","author":"Lander","year":"2018","journal-title":"Transl Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.schres.2026.04.016","article-title":"Risk and management of cancer in clozapine users: a systematic review","volume":"294","author":"Verdoux","year":"2026","journal-title":"Schizophr Res"},{"key":"B11","unstructured":"There is life after the UK Clozapine Central Non-Rechallenge Database\n          \n          \n            \n              Ebenezer\n              O\n            \n            \n              Casetta\n              C\n            \n            \n              Dzahini\n              O\n            \n            \n              Aviv\n              S\n            \n            \n              Gaughran\n              F\n            \n            \n              Shergill\n              S\n            \n          \n          10.1093\/schbul\/sbab006\n          \n          2021"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland","volume":"169","author":"Atkin","year":"1996","journal-title":"Br J Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40596-021-01582-0","article-title":"Evaluating the effectiveness of an educational module for the Bush-Francis Catatonia Rating Scale","volume":"46","author":"Wortzel","year":"2022","journal-title":"Acad Psychiatry"},{"key":"B14","unstructured":"Factor analysis and validation of the Bush Francis catatonia rating scale-Spain version\n          \n          \n            \n              Serrat\n              F\n            \n            \n              Cuevas-Esteban\n              J\n            \n            \n              Baladon\n              L\n            \n            \n              Rabaneda-Lombarte\n              N\n            \n            \n              D\u00edez-Quevedo\n              C\n            \n            \n              Iglesias-Gonz\u00e1lez\n              M\n            \n          \n          \n          2023"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.11.005","article-title":"Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy","volume":"92","author":"Markman","year":"2004","journal-title":"Gynecologic Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/BF00606409","article-title":"Agranulocytosis during treatment with chlozapine","volume":"11","author":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.20892\/j.issn.2095-3941.2020.0069","article-title":"Current management of chemotherapy-induced neutropenia in adults: key points and new challenges","volume":"17","author":"Ba","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B18","article-title":"The timing of chemotherapy-induced neutropenia and its clinical and economic impact","volume":"20","author":"Ozer","year":"2006","journal-title":"Oncol (Williston Park)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2147\/lctt.s6499","article-title":"Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis","volume":"1","author":"Wakelee","year":"2010","journal-title":"Lung Cancer: Targets Ther"},{"key":"B20","volume-title":"Docetaxel Accord: Summary of product characteristics","year":"2025"},{"key":"B21","unstructured":"CARBOPLATIN- carboplatin injection, solution\n          \n          \n          2016"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1016\/B0-12-370879-6\/00409-9","article-title":"TUMORS, MALIGNANT | Chemotherapeutic agents","volume-title":"Encyclopedia of respiratory medicine","author":"Edelman","year":"2006"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2014.05.007","article-title":"Continuation of clozapine during chemotherapy: a case report and review of literature","volume":"55","author":"Cunningham","year":"2014","journal-title":"Psychosomatics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13285","article-title":"Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: a systematic review of the literature","volume":"103","author":"Grainger","year":"2019","journal-title":"Eur J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4103\/aip.aip_177_23","article-title":"Clozapine withdrawal catatonia: a case series and review of literature","volume":"8","author":"Jagota","year":"2024","journal-title":"Ann Indian Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab103","article-title":"Reducing the risk of withdrawal symptoms and relapse following clozapine discontinuation\u2014Is it feasible to develop evidence-based guidelines","volume":"48","author":"Blackman","year":"2021","journal-title":"Schizophr Bull"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1863699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:26Z","timestamp":1791260726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1863699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1863699"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1863699","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1863699"}}